In a medium sized comparative effectiveness trial that recruited both Type 2 diabetes and overt diabetes at <21 weeks' gestation, insulin detemir improved a composite neonatal outcome and was associated with improved maternal outcomes including a reduction in maternal hypoglycaemia and hypertensive disorders compared to NPH.15 This evidence concerns the gene INS and hypertensive disorder.